Nektar Therapeutics (NKTR) Interest Expenses (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Interest Expenses of $7.9 million for Q1 2026, up 59.67% year-over-year from $5.0 million in Q1 2025, and down 18.7% quarter-over-quarter from $9.8 million in Q4 2025.
Nektar Therapeutics (NKTR) Interest Expenses (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 59.67% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $29.2 million (up 5.8% YoY), while the FY2025 annual figure was $892.4 million, up 3.88% from the prior year.
- Interest Expenses for Q1 2026 stood at $7.9 million, down from $9.8 million in the prior quarter.
- The five-year high for Interest Expenses was $10.2 million in Q4 2024, with the low at $5.0 million in Q1 2025.
- The 5-year median for Interest Expenses is $6.4 million (2024), against an average of $6.9 million.
- Peak annual rise in Interest Expenses reached 132.17% in 2022, while the deepest fall reached 45.68% in 2022.
- Nektar Therapeutics' Interest Expenses stood at $7.2 million in 2022, then decreased by 4.64% to $6.9 million in 2023, then surged by 47.85% to $10.2 million in 2024, then slipped by 3.78% to $9.8 million in 2025, then dropped by 18.7% to $7.9 million in 2026.
- Business Quant data shows NKTR's Interest Expenses at $7.9 million in Q1 2026, $9.8 million in Q4 2025, and $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.94 Mn |
| Mar 31, 2026 | 7.94 Mn |
| Dec 31, 2025 | 9.77 Mn |
| Dec 31, 2025 | 9.77 Mn |
| Sep 30, 2025 | 6.05 Mn |
| Sep 30, 2025 | 6.05 Mn |
| Jun 30, 2025 | 5.39 Mn |
| Jun 30, 2025 | 5.39 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 10.15 Mn |
| Dec 31, 2024 | 10.15 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Jun 30, 2024 | 6.41 Mn |
| Jun 30, 2024 | 6.41 Mn |
| Mar 31, 2024 | 5.53 Mn |
| Mar 31, 2024 | 5.53 Mn |
| Dec 31, 2023 | 6.87 Mn |
| Dec 31, 2023 | 6.87 Mn |